Widely used NSAID (non-steroidal anti-inflammatory drug: market share approx. 65%) with pronounced analgesic, antipyretic, antiphlogistic opioid-sparing effect. Also possible as an analgesic enhancing additive to paracetamol or metamizole (balanced analgesia).
Images (1)
Diclofenac
DefinitionThis section has been translated automatically.
PharmacokineticsThis section has been translated automatically.
Very potent antiphlogistic analgesic (10-20 times more potent against COX-2 than against COX-1).
IndicationThis section has been translated automatically.
Inflammation, painful swelling, rheumatoid arthritis, arthrosis.
Since increased COX 2 levels in carcinoma in situ, type "actinic keratosis" can be detected (also in spinocellular carcinomas), a 3% local therapeutic agent (diclofenac-hyaluronic acid gel) is successfully used for actinic keratoses.
Dosage and method of useThis section has been translated automatically.
2 times/day 50-150 mg p.o., i.m., i.v.
Undesirable effectsThis section has been translated automatically.
Systemic therapy: gastrointestinal ulcers, exanthema, photosensitivity.
With local application: redness, itching and rarely allergic contact reactions.
PreparationsThis section has been translated automatically.
- Voltaren®, Duravolten®, Effekton®, Diclofenac-ratiopharm®.
- Solaraze® (local therapeutic agent)
Note(s)This section has been translated automatically.
The combination of diclofenac with another mixed NSAID like ibuprofen/naproxen (inhibition of cyclooxygenases 1 and 2) or a selective COX-2 inhibitor like parecoxib is contraindicated.
LiteratureThis section has been translated automatically.
- Jage J (2009) Key questions on the therapy of postoperative pain. Georg Thieme Publishing House, Stuttgart S.16-21
- Merk HF (2007) Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46: 8-12